Hope on the horizon: Dr. Chandana contributed to a first-in-human, phase 1 clinical trial evaluating ABBV-706, a novel antibody-drug conjugate designed to target SEZ6 (Seizure-related homolog 6) a protein commonly expressed in small cell lung cancer (SCLC). These early findings highlight the potential of SEZ6-targeted therapies as a new treatment approach for patients with aggressive and difficult-to-treat lung cancers, where current options remain limited. CLICK HERE to read the full article and study.